Overview

Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC)

Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate the value of induction Erlotinib therapy before thoracotomy or radiotherapy in ⅢA-N2 (confirmed by mediastinoscopy or PET) non-small cell lung cancer (NSCLC) selected by epidermal growth factor receptor (EGFR) gene analysis and initial to explore a new treatment strategy for ⅢA-N2 NSCLC.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Guangdong Provincial People's Hospital
Treatments:
Carboplatin
Erlotinib Hydrochloride
Gemcitabine
Criteria
Inclusion Criteria:

- Written informed consent

- Histological or cytological documented

- Resectable NSCLC of stage IIIA-N2 confirmed by mediastinoscopy or PET

- Naive therapy NSCLC

- Candidates should be tolerated with induction therapy and thoracotomy with ECOG
performance status 0-2, adequate haematological and Hepatic- renal function and
qualified lung function

- Enough tissue samples to perform gene analysis

Exclusion Criteria:

- Small cell lung cancer

- Pregnant or breast-feeding women

- Any unstable systemic disease

- Patients with exposure to investigational drug therapy or other concurrent anticancer
therapy outside of this trial